Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Status:
RECRUITING

Trial end date:
2035-07-01

Target enrollment:

Participant gender:

To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

PHASE2

M.D. Anderson Cancer Center

Novartis Pharmaceuticals

asciminib